Jazz Pharmaceuticals plc Common Stock (Ireland) Earnings Dividend

Jazz Pharmaceuticals plc Common Stock (Ireland)’s revenue jumped 15.55% since last year same period to $1208.3Mn in the Q2 2026. On a quarterly growth basis, Jazz Pharmaceuticals plc Common Stock (Ireland) has generated 13.04% jump in its revenue since last 3-months.

Jazz Pharmaceuticals plc Common Stock (Ireland)’s net profit jumped 126.83% since last year same period to $192.8Mn in the Q2 2026. On a quarterly growth basis, Jazz Pharmaceuticals plc Common Stock (Ireland) has generated -34.22% fall in its net profits since last 3-months.

Jazz Pharmaceuticals plc Common Stock (Ireland)’s net profit margin jumped 123.22% since last year same period to 15.96% in the Q2 2026. On a quarterly growth basis, Jazz Pharmaceuticals plc Common Stock (Ireland) has generated -41.81% fall in its net profit margins since last 3-months.

Jazz Pharmaceuticals plc Common Stock (Ireland)’s earning per share (EPS) estimates for the current quarter stand at 5.06 - a 8.58% jump from last quarter’s estimates.

Jazz Pharmaceuticals plc Common Stock (Ireland)’s earning per share (EPS) estimates for the current year stand at 5.06.

Jazz Pharmaceuticals plc Common Stock (Ireland)’s earning per share (EPS) jumped 159.27% since last year same period to 4.89 in the Q2 2026. This indicates that the Jazz Pharmaceuticals plc Common Stock (Ireland) has generated 159.27% annual rate of jump in its earning per share (EPS) in the last 4 quarters.